migraine in kids


The American Academy of Neurology just published 2 guidelines on migraine in kids, one on prevention and one on treatment (see migraine pedi prevention neuro2019 in dropbox, or doi:10.1212/WNL.0000000000008105 and
migraine pedi treatment neuro2019 in dropbox, or doi:10.1212/WNL.0000000000008095)

---------------------
Migraine prevention

-- 15 studies on migraine prevention in children and adolescents met criteria, from 2000-2017

-- medications:
    -- topiramate: more likely than those receiving placebo to have a decrease in the frequency of migraine or headache days, moderate confidence in the evidence, standardized mean difference (SMD) relatively low at 0.391 (0.127 to 0.655)
        -- insufficient evidence whether topiramate leads to at least a 50% reduction in headache frequency, very low confidence in the evidence
    -- divalproex:
        -- insufficient evidence to determine whether children with migraine are more or less likely to have reduction in headache frequency, very low confidence in evidence
    -- amitriptyline
        -- insufficient evidence that there is a decrease in migraine frequency for migraine related disability, very low confidence of evidence
    -- propranolol
        -- possibly more likely to have at least a 50% reduction in headache attacks, low confidence in the evidence, RR 5.20 (1.59- 17.00); however, a large effect magnitude
    -- flunarizine (a calcium channel blocker, not available in the US)
        -- insufficient evidence that this leads to a decrease in migraine attacks, very low confidence in the evidence
    --cinnarizine (calcium channel blocker, not available in the US):
        -- probably more likely to have a reduction in headache frequency, SMD 0.83 (0.31- 1.35), significant magnitude of effect; also probably more likely to have reduction in headache severity and possibly more likely to have at least a 50% reduction in headache
    -- nimodipine
        -- insufficient evidence that it decreases migraine attacks, very low confidence in the evidence
    --onabotulinumtoxinA
        -- insufficient evidence of reduction in headache frequency, very low confidence in the evidence
-- medications combined with CBT
    -- children 10 to 17yo: amitriptyline with CBT was more likely to lead to a reduction in headache frequency than amitriptyline with headache education, SMD 0.48 (0.14- 0.82), high confidence of evidence; also, at least a 50% reduction in headache frequency (also probably more likely than those receiving amitriptyline with headache education to have reduction in the headache-related disability, moderate confidence in the evidence)

Recommendations:

-- clinicians should counsel patients/families of lifestyle and behavioral factors may influence headache frequency. Migraine is associated with a family history of migraine as well as with female sex. Potentially modifiable factors include overweight, caffeine, alcohol, lack of physical activity, poor sleep habits, and tobacco exposure. Depression is also associated with higher headache disability in adolescents. Weight loss can reduce the frequency in those who are overweight, level B recommendation

-- preventive medicines may decrease the frequency and disability of migraine, as well as acute headache medication overuse, level B recommendation. Though there are no data in the pediatric population (ie, this is from adults): headaches on more than 6 days a month is a risk factor for progression to chronic migraine as well as medication overuse for the migraines.

-- There was a pretty remarkable placebo effect in children, with 30 to 61% on placebo having a 50% or greater reduction in headache frequency. Patients/caregivers should understand that there was a high rate of improvement with placebo and that the majority of preventive medications were not superior to placebo, level B recommendation
-- clinician should discuss the potential benefit or amitriptyline combined with CBT (amitriptyline does have an FDA black box  warning regarding suicidal thoughts and behavior in children and adolescents), topiramate, and propranolol; and there should be shared decision-making regarding the use of short-term treatment trials, with a minimum 2 months, all with level B recommendation

-- For patients of childbearing potential: consider the potential teratogenic effects of valproate and topiramate, Level A recommendation. Also, topiramate may decrease the efficacy of oral combined hormonal contraceptives; clinician should also recommend daily folic acid supplementation for those on topiramate or valproate, level A recommendation

-- Children and adolescents with migraine should be screened for mood and anxiety disorders, since they are at increased risk of headache persistence; however high quality evidence suggests that these children are not at a greater risk of developing recurrent headache. Clinicians should screen for mood and anxiety disorders and management options, level B recommendation


---------------------------------------------------------------------------------------------------------------------
Migraine Treatment

 Recommendations:

--establish a specific headache diagnosis
    --diagnostic criteria for children/adolescents include: at least 5 headaches/yr that lasted 2-72 hours if untreated (time kid sleeps can be considered part of duration), and 2 of 4 of: pulsatile quality, unilateral, worsening with activity or limiting activity, moderate to severe in intensity; and associated with at least nausea, vomiting, photophobia or phonophobia
    --auras occur in 1/3 of older kids and adolescents and precede headache by 5-60 minutes
    --clinicians should ask about premonitory and aura symptoms; onset, location, quality, severity, frequency, duration, and aggravating/alleviating factors; associated symptoms of nausea, vomiting, phonophobia and photophobia; and pain-related disability, level B recommendation

-- acute migraine treatment
    --in adults, early treatment (eg <1hr) improves pain-free rates, and likely also in kids (level B recommendation for kids)
    --many benefit from nonprescription acetaminophen, ibuprofen and naproxen
    --triptans are less commonly used than in adults, with FDA prescribing restrictions:
        --almotriptan (age 12 and older)
        --rizatriptan (aged 6-17)
        --sumatriptan/naproxen (age 12 and older)
        --zomitriptan nasal (age 12 and older).
    --ergots and naproxen alone have not been studied in kids
    --recommendation: trying ibuprofen first (10mg/kg), level B recommendation
    --recommendation: adolescents—sumatriptan/naproxen combo (10/60, 30/180, 85/500 mg); zolmitriptan nasal spray (5mg), sumatriptan nasal spray (20mg), rizatriptan oral dissolving tabs ( 5 or 10mg), almotriptan (6.25 or 12.5 mg), level B recommendation

-- other medication issues:
    --adult patients do respond differently to different meds; nonresponse to one triptan does not preclude response to another (level B recommendation for kids)
    --a second dose of triptan may be effective in adults who respond but the headache recurs within 24 hours (level B recommendation for kids)
       --the same may be true for kids but daily maximum doses suggested should not be exceeded
    --nasal sumatriptan and zolmitriptan are absorbed more rapidly than oral meds and have quicker onset of action; these may be preferred in those with nausea/vomiting or if headache pain severity  peaks quickly (level C recommendation)
    --sumatriptan/naproxen combo (10/60, 30/180, 85/500 mg) is more likely than placebo to result in pain-free status within 2 hours
    --in adolescents with incomplete response to triptan, consider offering ibuprofen or naproxen in combo with triptan (insurance may not cover the combo meds or may cost lots more, so may need to just add NSAID), level B recommendation
    --in pediatric trials, the effects of meds on migraine-associated symptoms is less pronounced than for pain. So, those with prominent nausea/vomiting  should be offered additional antiemetics as appropriate for age, level B recommendation

-- counseling:
    --counsel children/adolescents/families about lifestyle modification, identification/minimization of migraine triggers or aggravating factors, level B recommendation
    --maintain headache diary to monitor treatment response, level B recommendation
    --avoid medication overuse, level B recommendation:
        --no more than 14 days of ibuprofen or acetaminophen/month
        --no more than 9 days/month of triptans or any combo of triptans and analgesics, or more than 3 months total of opiates [they note that opiates are included without any supportive evidence because they are included in other migraine guidelines]

--  contraindications and precautions to triptans
    --per FDA, contraindicated if history cardiovascular disease (incl stroke, TIA, MI, severe peripheral artery dz, ischemic bowel dz, and coronary vasospasm; cardiac accessory conduction pathway disorders.
    --their recommendation: contraindicated if history of ischemic vascular disease or accessory conduction pathway disorders, which can be exacerbated by triptans, level A recommendation

-- migraine with aura
    --in adults with aura, safe to take triptans during aura but may be more effective at onset of pain, though caution is warranted in those with aura given that it can be difficult to differentiate the aura from early stroke symptoms, esp if the aura is non-visual one. Contraindicated by FDA in those with complex auras (eg hemiplegic or brainstem aura), though this was based on old understanding of migraine pathophysiology
    --recommendation that adolescents can take triptan during their typical migraine aura though may be more effective at time of pain onset, level B recommendation)

so, useful review. a few points:
--for prevention:
    --it is really remarkable how impressive the placebo effect is on kids with migraine. This speaks to using the least toxic drugs available first (and ??having a prescribable placebo??)
    --there are other drugs that work pretty well in adults, including other b-blockers than propranolol, venlafaxine, some calcium channel blockers (eg verapamil)
        --other tricyclics seem to work as well as amitryptiline and have many fewer adverse effects. especially desipramine and nortriptyline (though lacking rigorous studies of efficacy, these meds in clinical practice seem to work as well for migraine, and also other indications: eg neuropathies)
    --other lifestyle changes that seem to help control migraine include regular exercise, improving sleep when that is an issue, and routine meal schedules

for prior blogs on placebo, see
http://gmodestmedblogs.blogspot.com/2015/04/placebo-genetics-and-placebome.html for some general thoughts on placebos and evidence that there is a genetic predisposition to placebo response (the “placebome” for the areas of the genome associated with this)
http://gmodestmedblogs.blogspot.com/2016/11/benefits-of-placebo-for-low-back-pain.html for an article on placebo effect in patients with low back pain, even when the patient knows that they are getting a placebo!!

 geoff​

If you would like to be on the regular email list for upcoming blogs, please contact me at gmodest@uphams.org


to get access to all of the blogs:
1. go to http://gmodestmedblogs.blogspot.com/ to see them in reverse chronological order
2. click on 3 parallel lines top left, if you want to see blogs by category, then click on "labels" and choose a category​
3. or you can just click on the magnifying glass on top right, then  type in a name in the search box and get all the blogs with that name in them

please feel free to circulate this to others. also, if you send me their emails, i can add them to the list



Comments

Popular posts from this blog

air pollution and heart disease

UPDATE: ASCVD risk factor critique

visceral fat loss is sustained long-term